Drug guidance
Tolvaptan for treating autosomal dominant polycystic kidney disease
Condition
Kidney
4 June 2024
Published on 04 Jun 2024
Last Updated on 04 Jun 2024
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended tolvaptan for inclusion on the MOH List of Subsidised Drugs for treating autosomal dominant polycystic kidney disease (ADPKD). The decision was based on the uncertain extent of clinical benefit, and because tolvaptan was unlikely to represent a cost-effective use of healthcare resources for treating ADPKD.